Aurobindo Pharma Acquires Non-Oncology Prescription Formulations Business of Khandelwal Laboratories

Aurobindo Pharma Ltd has approved the acquisition of the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited through a Business Transfer Agreement. The Business, which includes inventory, intellectual property, employees, contracts, etc., generated a turnover of INR 1,135.3 Mn in FY2024-25 with an EBITDA of INR 289.9 Mn. It has around 470 people strong field force and more than 1600 stockists. The acquisition does not fall within the definition of related party transaction and the promoter/promoter group/group companies do not have any interest in the Business being acquired. The acquisition will add further brands in pain management and anti-infective, complementing the existing product portfolios of the Company and helping in expanding its business in the domestic market. The transaction has been signed and closed on January 1, 2026.